Navigating the evolving MFN landscape
Strategic insights and solutions for pharmaceutical and biotech companies
Most Favored Nation (MFN) pricing marks a tectonic shift in the US healthcare landscape with global P&MA implications. For the first time US prices are interconnected with prices outside the U.S., and not just at the list price level, but also on the net price level. As US revenues typically make up 60-70% of an asset’s value, manufacturers must navigate this sea of change with a robust strategy, or risk an epic failure by launching innovative pharmaceuticals on a global base without taking MFN into account across a product’s full product lifecycle.
This hub brings together the latest insights, policy updates, and expert analysis to help you stay informed, respond with confidence, and make better pricing and market access decisions.
Our services and capabilities
Latest insights

Blog
Between Scylla and Charybdis: Pharma launch strategy in the MFN era
As MFN pricing reshapes the global pharmaceutical landscape, launch strategy has become a high-stakes balancing act. Discover how pharma leaders can navigate the trade-offs between protecting US revenues, sustaining global access, and preserving long-term innovation.

BLOG
After Scylla and Charybdis: The many possible futures of MFN drug pricing
One year into the MFN era, the debate has shifted from whether pharmaceutical pricing will change to how. This article explores the possible futures of MFN drug pricing, examining the strategic scenarios that could emerge as companies, governments, and healthcare systems adapt to a new global pricing reality. Discover what these developments could mean for market access, innovation, and the future of pharmaceutical commercialization.
Contact our experts
Kontakt
Nehmen Sie Kontakt zu uns auf, unser Team berät Sie gerne.






